/ /

shingles vaccine

Immune responses to the latest shingles vaccine (Shingrix) last for at least three years following vaccination. The robust immune responses develop and persist in all age groups, according to a recent study in The Journal of Infectious Diseases.
GSK Launches More Effective Shingles Vaccine
GSK Launches More Effective Shingles VaccineWill Shingrix become the new go-to shingles vaccine?
FDA approved the herpes zoster vaccine (Shingrix, GlaxoSmithKline) to treat shingles in adults aged 50 years and older.
Managed care and hospital decision-makers are in a key position to “move the needle” at the system level on improving adult immunization coverage rates in the United States.
Ophthalmologists in support of routine vaccinations for herpes zoster (shingles) can take steps to offer their older patients more protection against the ocular complications of the disease.
Herpes zoster vaccine continues to be effective in protecting older adults against shingles, even after they undergo chemotherapy, a study published August 4 in Clinical Infectious Diseases.
Personal knowledge of or experience with shingles may be a major driver in a consumer's decision about whether to receive the shingles vaccine, according to a Harris Interactive consumer awareness survey sponsored by Merck.
Zoster vaccination was associated with a reduction in post-herpetic neuralgia among those who are aged 65 and older, according to a study, published in PLoS Medicine. However, they also found that the use of the shingles vaccine was also very low among certain population groups